IMA203

IMA203 · Immatics US, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMA203, covering 2026-04-13 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma [Phase 3]

See pricing